Neuroleptic malignant syndrome in children and adolescents.
Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J.
Columbia University, College of Physicians and Surgeons, St. Luke's/Roosevelt Hospital Center, New York, NY 10025, USA.
OBJECTIVE: Neuroleptic malignant syndrome (NMS) is a serious iatrogenic condition. This report reviews the world literature to characterize the syndrome and evaluate factors that promote early detection and effective intervention. METHOD: The review identified 77 NMS cases (49 males, 27 females, 1 gender unknown); ages ranged from 0.9 to 18 years (mean 14.8 +/- 3.96). Univariate and multiple regression analyses were applied to 38 variables to identify early signs of the disorder, to identify correlates of outcome, and to evaluate treatments. RESULTS: The duration of NMS spanned from 1 to 119 days. Nine percent of patients died and 20% resolved with serious sequelae. Patients receiving low-potency neuroleptics had a poorer outcome (p = .01). Fever was related to longer duration of illness (p = .03). Anticholinergics and bromocriptine were effective and without fatalities, but dantrolene was not useful in this sample of children and adolescents. CONCLUSIONS: Early detection and appropriate interventions appear important in moderating the course and outcome of NMS.
Publication Types:
PMID: 9951218 [PubMed - indexed for MEDLINE]